Contra-indicated in patients with severe renal impairment, end stage renal disease, or on dialysis.
Glyxambi is empagliflozin and linagliptin; Synjardy is empagliflozin and metformin.
- TRADE NAMES: Glyxambi (Boehringer Ingelheim); Jardiance (Boehringer Ingelheim); Synjardy (Boehringer Ingelheim)
- INDICATIONS: Type II diabetes mellitus. Repurposed for the treatment of glycogen storage disease type Ib (GSD Ib).
- CLASS: Antidiabetic, Sodium-glucose co-transporter 2 (SGLT2) inhibitor ('gliflozin')
- HALF-LIFE: 12 hours
- FDA APPROVAL DATE: 08/01/2014
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
Sodium-glucose co-transporter 2 (SGLT2) inhibitor ('gliflozin')
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE links (above) to see two reviews of empagliflozin in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 06/10/2025
